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The International Stroke Trial (IST) and the
Chinese Acute Stroke Trial (CAST) 
Why are these studies important and
noteworthy?
The International Stroke Trial and Chinese Acute
Stroke Trial were two landmark trials performed to assess
the efficacy of aspirin in patients with acute stroke, within
48 hours of stroke onset. The role of aspirin in secondary
prevention of serious vascular events was well established,
but before these two trials there was no large scale
randomized evidence on aspirin in acute ischaemic stroke. 
The authors suggested that with several million
people afflicted with ischaemic stroke every year, if only 10
or 20 per thousand could be saved from death or
dependency, the overall impact would be huge. Pakistan is
the sixth most populous country in the world with a
population of over 120 million - translated into absolute
numbers; these results have important implications for
Pakistan.
IST also looked at the effect of heparin on death or
dependency. The rationale was that heparin has a
mechanism of action that is distinct from aspirin and so the
combination might be more effective than either alone.
The balance of risk and benefit for heparin and
aspirin was uncertain in acute stroke. Also, there was a wide
variation in clinical practice, and a great uncertainty in the
minds of many physicians regarding the safety and efficacy
of these drugs. 
There are in actual evidence based practice very few
interventions that positively impact outcome after acute
stroke and have a strong evidence base to support them.
There still remains a large gap between available evidence
and actual implementation.
Who were the participants?
CAST included 21106 patients from 413 hospitals in
China. These were patients judged to be within 48 hours of
the onset of symptoms of acute ischaemic stroke, and had
no clear indication for or contraindication to aspirin, based
on the physician's judgment. The fundamental criterion was
that the responsible physician was uncertain whether aspirin
treatment was indicated or not. A CT scan before
randomization was mandatory only for patients who were
comatose. 
IST included 19435 patients from 467 hospitals in 36
countries. Amongst these were 229 patients from India, 9
from Japan, 140 from Singapore and 20 from Sri Lanka.
The majority of patients were of European descent. These
patients were also included within 48 hours of stroke onset,
and CT was mandatory only for comatose patients. 
Thus both studies had a simple design and a wide
recruitment and certainly the impressive numbers to draw
broadly relevant conclusions.
What was the intervention?
In CAST 10554 patients were randomly assigned
Aspirin 160 mg per day, and 10552 were assigned matching
placebo. Randomization was by prepacked, sequentially
numbered trial envelopes, each containing calendar-packed
aspirin or placebo, produced centrally. 
IST was more complicated. Using a factorial design,
half the patients were randomized to aspirin and half to
'avoid aspirin'. Similarly half were randomized to heparin,
and half to 'avoid heparin'. Therefore of the 19,435
randomized, 4858 were randomized to 300 mg Aspirin only,
2432 to 300mg Aspirin and 5000 u heparin, 2430 to 300mg
Aspirin and 12500 u of heparin, 2429 to 5000u of heparin
only, and 2426 to 12500 u of heparin. 4860 were given
neither heparin nor aspirin.
What was the outcome?
In CAST the participants were well matched in
terms of age, mean times from onset of symptoms, blood
pressures, gender, consciousness and stroke subtype.
Patients were followed for up to 4 weeks and during this
time, the proportional reduction in the odds of death in the
aspirin group was 14% which was significant (p<0.01)and
translated to an absolute difference of 5.4 fewer deaths per
1000 patients allocated to aspirin. For the endpoint of fatal
and non-fatal recurrent stroke, the difference was not
significant, however, it combined a significant reduction
of 4.7 recurrent ischaemic strokes per 1000 with a non
significant excess of 2.1 haemorrhagic strokes per 1000.
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For the primary outcome of dead or dependant at
discharge, there was a non significant trend favouring
those allocated aspirin.
In IST also, the two groups were well matched. But
IST differed from CAST in several respects. In CAST 63%
were males, as opposed to 54% in IST, 72% were younger
than 70 years as opposed to 39% in IST, 13% were drowsy
or comatose as opposed to 23% in IST. Among aspirin
allocated patients there were non-significantly fewer deaths
within 14 days corresponding to 4 fewer deaths per 1000
patients. At six months, a smaller percentage seemed to be
dead or dependant in the aspirin arm although this was again
not significant. After adjustment for baseline prognosis
however, the benefit from aspirin was significant. There
were fewer recurrent ischaemic strokes within 14 days in
the aspirin arm which was significant, and a non significant
excess of haemorrhagic strokes was noticed. Heparin on the
other hand showed significant reduction in recurrent
ischaemic events in the initial 14 days, but this benefit was
offset by a similar sized increase in haemorrhagic strokes. 
What were the conclusions?
CAST and IST were two large trials in about 40,000
randomized patients. They show that immediate use of
medium dose Aspirin (160 mg to 300 mg) produces a
modest, but definite net reduction in early death or non fatal
stroke. In these trials, aspirin caused about 2 haemorrhagic
strokes per 1000 patients treated, but also prevented about
11 other strokes or deaths in hospital, corresponding to a net
benefit or about nine deaths or non fatal strokes avoided for
every 1000 patients treated for a few weeks.
As for Heparin, neither dose regimen in IST offered
any clinical advantage. Subsequently, about 25 trials with
23,748 participants who received heparin or heparinoids for
acute stroke have shown that it has no net benefit in
improving outcomes from stroke regardless of dose, type of
anticoagulant, and mechanism of stroke (embolic, posterior
circulation etc). Therefore there is no evidence to support
the use of heparin in acute ischaemic strokes.
None of the other agents have been tested in the
acute setting; they have their place in secondary prevention.
How does this impact our clinical practice?
Before CAST and IST, there was no reliable
evidence that early aspirin use in the dose of 160 mg to 300
mg in acute ischaemic stroke was safe and efficacious. Now,
we know that with a cost effective treatment like a single
dose of aspirin per day (Rs 1) we can prevent around nine
deaths or non fatal strokes per 1000 patients treated. If this
is translated into the numbers who can benefit from therapy,
they would be in thousands. So when we have a patient with
an acute stroke, who is non comatose — the best medicine
is Aspirin at a dose of at least 150 mg. Heparin and
heparinoids are of no established benefit.
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